Alzheimer’s disease (AD) is highly heritable and recent studies have identified over 20
disease-associated genomic loci. Yet these only explain a small proportion of the genetic …

There is increasing evidence that subjective cognitive decline (SCD) in individuals with
unimpaired performance on cognitive tests may represent the first symptomatic manifestation of …

Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …

Background White matter hyperintensities (WMH), lacunes and microbleeds are regarded
as typical MRI expressions of cerebral small vessel disease (SVD) and they are highly …

In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

For many years, blood-based biomarkers for Alzheimer's disease seemed unattainable, but
recent results have shown that they could become a reality. Convincing data generated with …

Context Small single-center studies have shown that cerebrospinal fluid (CSF) biomarkers
may be useful to identify incipient Alzheimer disease (AD) in patients with mild cognitive …

A growing awareness about brain health and Alzheimer's disease in the general population
is leading to an increasing number of cognitively unimpaired individuals, who are …

Non-pharmacological therapies, such as physical activity interventions, are an appealing
alternative or add-on to current pharmacological treatment of cognitive symptoms in patients …

A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer’s disease neuropathological hallmarks (that is, amyloid-β …